Diligence memo · auto-generated · as of July 3, 2026
Nohla Therapeutics Inc.
Nohla Therapeutics Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Nohla Therapeutics Inc. operates in Biotechnology, based in SEATTLE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nohla Therapeutics Inc. has raised $79M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $45M on 2018-05-01.
Most recent recorded round closed around 2018-05-01.
Valuation (modeled)modeled
Provath models Nohla Therapeutics Inc. at approximately $1.8B (range $139M–$4.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.90× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era. Within the normal band (90% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 8.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 88% of Biotechnology peers (4293 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.